OBJECTIVE: Ovarian cancer has very heterogeneous histological classification, and response to therapy of the same grade and type varies. We studied genes in the Wnt and hedgehog (Hh) pathways, which are essential for embryonic development and which play critical roles in proliferation in a variety of human cancers. Variations in these pathway genes causing proliferation could play a role in the variation in tumor progression and response to therapy. METHODS/MATERIALS: Using real-time polymerase chain reaction, we studied 16 primary grade 3 International Federation of Gynecology and Obstetrics stage III serous ovarian cancer samples for expression of the Wnt pathway gene AXIN2, fibroblast growth factor 9, and Hh pathway gene expressions of glioma-associated oncogene 1, glioma-associated oncogene 2, patched homolog 1, patched homolog 2, Indian Hedgehog (HH), sonic HH, and Smoothened, a G protein-coupled receptor protein. Normal ovary epithelial cell line was used as control. RESULTS: We found wide variation of up-regulation of pathway component and target genes in the primary tumor samples and apparent cross talk between the pathways. AXIN2, a Wnt target gene, showed increased expression in all serous ovarian cancer samples. Fibroblast growth factor 9 was also overexpressed in all tumors with greater than 1000-fold increase in gene expression in 4 tumors. Expression of Hh pathway genes varied greatly. More than half of the tumor samples showed involvement of Hh signaling or pathway activation either by expression of transcription factors and Hh ligands or by overexpression of Indian HH/sonic HH and the receptor-encoding patched homolog 1/patched homolog 2. CONCLUSION: We found a wide variation in fold expression of genes involved in the Wnt and Hh pathway between patient samples.
OBJECTIVE:Ovarian cancer has very heterogeneous histological classification, and response to therapy of the same grade and type varies. We studied genes in the Wnt and hedgehog (Hh) pathways, which are essential for embryonic development and which play critical roles in proliferation in a variety of humancancers. Variations in these pathway genes causing proliferation could play a role in the variation in tumor progression and response to therapy. METHODS/MATERIALS: Using real-time polymerase chain reaction, we studied 16 primary grade 3 International Federation of Gynecology and Obstetrics stage III serous ovarian cancer samples for expression of the Wnt pathway gene AXIN2, fibroblast growth factor 9, and Hh pathway gene expressions of glioma-associated oncogene 1, glioma-associated oncogene 2, patched homolog 1, patched homolog 2, Indian Hedgehog (HH), sonic HH, and Smoothened, a G protein-coupled receptor protein. Normal ovary epithelial cell line was used as control. RESULTS: We found wide variation of up-regulation of pathway component and target genes in the primary tumor samples and apparent cross talk between the pathways. AXIN2, a Wnt target gene, showed increased expression in all serous ovarian cancer samples. Fibroblast growth factor 9 was also overexpressed in all tumors with greater than 1000-fold increase in gene expression in 4 tumors. Expression of Hh pathway genes varied greatly. More than half of the tumor samples showed involvement of Hh signaling or pathway activation either by expression of transcription factors and Hh ligands or by overexpression of Indian HH/sonic HH and the receptor-encoding patched homolog 1/patched homolog 2. CONCLUSION: We found a wide variation in fold expression of genes involved in the Wnt and Hh pathway between patient samples.
Authors: Kory J Lavine; Andrew C White; Changwon Park; Craig S Smith; Kyunghee Choi; Fanxin Long; Chi-chung Hui; David M Ornitz Journal: Genes Dev Date: 2006-06-15 Impact factor: 11.361
Authors: Neali D Hendrix; Rong Wu; Rork Kuick; Donald R Schwartz; Eric R Fearon; Kathleen R Cho Journal: Cancer Res Date: 2006-02-01 Impact factor: 12.701
Authors: Maria Notaridou; Lydia Quaye; Dimitra Dafou; Chris Jones; Honglin Song; Estrid Høgdall; Susanne K Kjaer; Lise Christensen; Claus Høgdall; Jan Blaakaer; Valerie McGuire; Anna H Wu; David J Van Den Berg; Malcolm C Pike; Aleksandra Gentry-Maharaj; Eva Wozniak; Tanya Sher; Ian J Jacobs; Jonathan Tyrer; Joellen M Schildkraut; Patricia G Moorman; Edwin S Iversen; Anna Jakubowska; Krzysztof Mędrek; Jan Lubiński; Roberta B Ness; Kirsten B Moysich; Galina Lurie; Lynne R Wilkens; Michael E Carney; Shan Wang-Gohrke; Jennifer A Doherty; Mary Anne Rossing; Matthias W Beckmann; Falk C Thiel; Arif B Ekici; Xiaoqing Chen; Jonathan Beesley; Jacek Gronwald; Peter A Fasching; Jenny Chang-Claude; Marc T Goodman; Georgia Chenevix-Trench; Andrew Berchuck; C Leigh Pearce; Alice S Whittemore; Usha Menon; Paul D P Pharoah; Simon A Gayther; Susan J Ramus Journal: Int J Cancer Date: 2011-05-01 Impact factor: 7.396
Authors: Donald R Schwartz; Rong Wu; Sharon L R Kardia; Albert M Levin; Chiang-Ching Huang; Kerby A Shedden; Rork Kuick; David E Misek; Samir M Hanash; Jeremy M G Taylor; Heather Reed; Neali Hendrix; Yali Zhai; Eric R Fearon; Kathleen R Cho Journal: Cancer Res Date: 2003-06-01 Impact factor: 12.701
Authors: Andrew C White; Jingsong Xu; Yongjun Yin; Craig Smith; Gregory Schmid; David M Ornitz Journal: Development Date: 2006-03-15 Impact factor: 6.868
Authors: Dorte L Egeberg; Mette Lethan; Robert Manguso; Linda Schneider; Aashir Awan; Tue S Jørgensen; Anne G Byskov; Lotte B Pedersen; Søren T Christensen Journal: Cilia Date: 2012-08-10
Authors: Caroline E Ford; Eve Jary; Sean Si Qian Ma; Sheri Nixdorf; Viola A Heinzelmann-Schwarz; Robyn L Ward Journal: PLoS One Date: 2013-01-11 Impact factor: 3.240